Coalition for Epidemic Preparedness Innovations (CEPI) first awarded INOVIO a grant of up to $9 million to fund ongoing preclinical and initial clinical development of INO-4800, INOVIO’s DNA vaccine for the coronavirus that causes COVID-19. CEPI then provided $6.9 million to INOVIO and the International Vaccine Institute for a Phase 1/2 study in South Korea with 160 participants.
In April 2018, CEPI awarded a grant of up to $56 million to support INOVIO’s pre-clinical and clinical advancement through Phase 2 of INO-4500, its Lassa fever vaccine, and INO-4700, its MERS vaccine. The agreement will enable funding for INOVIO’s development efforts over a five-year period. The partnership agreement also includes, not counted in the total above, to establish investigational stockpiles of both vaccines.